Rewiring urea cycle metabolism in cancer to support anabolism

[1]  David M. Wilson,et al.  Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures , 2018, Cell.

[2]  P. Cheng,et al.  Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models , 2018, Oncology reports.

[3]  G. Abou-Alfa,et al.  A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies , 2018, Cancer Chemotherapy and Pharmacology.

[4]  N. Danial,et al.  Grasping for aspartate in tumour metabolism , 2018, Nature Cell Biology.

[5]  K. Nathanson,et al.  Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity. , 2018, Cell metabolism.

[6]  F. Izzo,et al.  Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. V. Vander Heiden,et al.  Aspartate is an endogenous metabolic limitation for tumour growth , 2018, Nature Cell Biology.

[8]  D. di Bernardo,et al.  Induction of Nitric-Oxide Metabolism in Enterocytes Alleviates Colitis and Inflammation-Associated Colon Cancer , 2018, Cell reports.

[9]  M. Snuderl,et al.  Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumors , 2018, Nature Cell Biology.

[10]  P. L. Ipata,et al.  Metabolic interaction between urea cycle and citric acid cycle shunt: A guided approach , 2018, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.

[11]  Le Yin,et al.  Elevated mitochondrial SLC25A29 in cancer modulates metabolic status by increasing mitochondria-derived nitric oxide , 2018, Oncogene.

[12]  N. Tang,et al.  Optimizing combination of liver‐enriched transcription factors and nuclear receptors simultaneously favors ammonia and drug metabolism in liver cells , 2018, Experimental cell research.

[13]  A. Cheng,et al.  Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  A. Carracedo,et al.  Oil for the cancer engine: The cross-talk between oncogenic signaling and polyamine metabolism , 2018, Science Advances.

[15]  P. Kearns,et al.  The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100 , 2017, International journal of cancer.

[16]  L. Romer,et al.  Hypoxia Triggers SENP1 (Sentrin-Specific Protease 1) Modulation of KLF15 (Kruppel-Like Factor 15) and Transcriptional Regulation of Arg2 (Arginase 2) in Pulmonary Endothelium , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[17]  G. Abou-Alfa,et al.  A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma , 2017, Cancer.

[18]  Sarah Jeanfavre,et al.  Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass , 2017, Science.

[19]  Y. Xiong,et al.  CLOCK Acetylates ASS1 to Drive Circadian Rhythm of Ureagenesis. , 2017, Molecular cell.

[20]  Gregory A. Wyant,et al.  mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient , 2017, Cell.

[21]  W. Hung,et al.  A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients , 2017, Scientific Reports.

[22]  A. Deutsch,et al.  Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization , 2017, Molecular Cancer Therapeutics.

[23]  Daniel S. Hitchcock,et al.  Critical role for arginase 2 in obesity-associated pancreatic cancer , 2017, Nature Communications.

[24]  Edmund R. S. Kunji,et al.  Expression and putative role of mitochondrial transport proteins in cancer. , 2017, Biochimica et biophysica acta. Bioenergetics.

[25]  Wei He,et al.  PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration , 2017, Oncotarget.

[26]  E. Closs,et al.  Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression , 2017, Front. Immunol..

[27]  P. Cheng,et al.  Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies , 2017, Oncotarget.

[28]  Kristie L. Rose,et al.  Critical role of SIK3 in mediating high salt and IL-17 synergy leading to breast cancer cell proliferation , 2017, PloS one.

[29]  S. Venneti,et al.  Glutaminolysis: A Hallmark of Cancer Metabolism. , 2017, Annual review of biomedical engineering.

[30]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[31]  F. del Caño-Ochoa,et al.  Structural Insight into the Core of CAD, the Multifunctional Protein Leading De Novo Pyrimidine Biosynthesis. , 2017, Structure.

[32]  Chiara Secondini,et al.  Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade , 2017, Oncoimmunology.

[33]  C. Thompson,et al.  Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine , 2017, The EMBO journal.

[34]  C. Tanikawa,et al.  Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53 , 2017, Science Advances.

[35]  Benjamin P. C. Chen,et al.  CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells , 2017, Nature.

[36]  G. Cook,et al.  Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Xiaomin Ying,et al.  Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues , 2017, Scientific Reports.

[38]  A. Vashisht,et al.  Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes , 2017, Molecular and Cellular Biology.

[39]  N. Tang,et al.  The activity of the carbamoyl phosphate synthase 1 promoter in human liver‐derived cells is dependent on hepatocyte nuclear factor 3‐beta , 2017, Journal of cellular and molecular medicine.

[40]  C. Skibola,et al.  Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity. , 2017, ACS chemical biology.

[41]  Jeffrey E. Lee,et al.  Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma , 2017, PloS one.

[42]  G. Stephanopoulos,et al.  Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors , 2016, Nature Medicine.

[43]  Jennifer B Dennison,et al.  Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. , 2017, Journal of the National Cancer Institute.

[44]  D. Hansel,et al.  Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase. , 2017, The American journal of pathology.

[45]  M. Lai,et al.  Silencing of argininosuccinate lyase inhibits colorectal cancer formation. , 2017, Oncology reports.

[46]  S. Beck,et al.  Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial , 2017, JAMA oncology.

[47]  H. Shimizu,et al.  Metabolic Adaptation to Nutritional Stress in Human Colorectal Cancer , 2016, Scientific Reports.

[48]  A. De Grassi,et al.  AGC1/2, the mitochondrial aspartate-glutamate carriers. , 2016, Biochimica et biophysica acta.

[49]  M. V. Vander Heiden,et al.  Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. , 2016, Cell metabolism.

[50]  B. V. Van Tine,et al.  A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas , 2016, Cell Death and Disease.

[51]  M. Mann,et al.  L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity , 2016, Cell.

[52]  Jeffrey T. Chang,et al.  Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation , 2016, Oncotarget.

[53]  A. Kawai,et al.  Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance , 2016, Oncotarget.

[54]  D. Fukumura,et al.  Arginine dependence of tumor cells: targeting a chink in cancer’s armor , 2016, Oncogene.

[55]  Emanuel J. V. Gonçalves,et al.  Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition , 2016, Nature.

[56]  P. Szlosarek,et al.  Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1 , 2016, Cell reports.

[57]  Ashok Palaniappan,et al.  Computational Identification of Novel Stage-Specific Biomarkers in Colorectal Cancer Progression , 2016, PloS one.

[58]  G. Shulman,et al.  Argininosuccinate synthetase regulates hepatic AMPK linking protein catabolism and ureagenesis to hepatic lipid metabolism , 2016, Proceedings of the National Academy of Sciences.

[59]  Shuang Liu,et al.  PGC-1α Promotes Ureagenesis in Mouse Periportal Hepatocytes through SIRT3 and SIRT5 in Response to Glucagon , 2016, Scientific reports.

[60]  D. A. Foster,et al.  Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells* , 2016, The Journal of Biological Chemistry.

[61]  Jie Yuan,et al.  Multiple regulation pathways and pivotal biological functions of STAT3 in cancer , 2015, Scientific Reports.

[62]  M. Lai,et al.  Argininosuccinate lyase is a potential therapeutic target in breast cancer. , 2015, Oncology reports.

[63]  Senlin Ma,et al.  Co-expression of the carbamoyl-phosphate synthase 1 gene and its long non-coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma , 2015, Molecular medicine reports.

[64]  E. Ruppin,et al.  Diversion of aspartate in ASS1-deficient tumors fosters de novo pyrimidine synthesis , 2015, Nature.

[65]  A. Vazquez,et al.  Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis , 2015, Nature Cell Biology.

[66]  M. V. Heiden,et al.  Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells , 2015, Cell.

[67]  C. Dang,et al.  MYC and metabolism on the path to cancer. , 2015, Seminars in cell & developmental biology.

[68]  D. Sabatini,et al.  An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis , 2015, Cell.

[69]  Y. Bhutia,et al.  Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. , 2015, Cancer research.

[70]  Eyal Gottlieb,et al.  Oncometabolites: tailoring our genes , 2015, The FEBS journal.

[71]  M. Lai,et al.  Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines , 2015, Scientific Reports.

[72]  K. Kelly,et al.  Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors , 2015, Clinical Cancer Research.

[73]  M. V. Vander Heiden,et al.  Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. , 2015, Cancer research.

[74]  H. Erbaş,et al.  Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. , 2014, Balkan medical journal.

[75]  S. Fan,et al.  Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma , 2015, Investigational New Drugs.

[76]  D. Nguyen,et al.  Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. , 2014, Anticancer research.

[77]  L. Boon,et al.  C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation , 2014, Oncogenesis.

[78]  P. Mariottini,et al.  Polyamines metabolism and breast cancer: state of the art and perspectives , 2014, Breast Cancer Research and Treatment.

[79]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[80]  Ting-feng Wu,et al.  Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy , 2014, Tumor Biology.

[81]  Yingming Zhao,et al.  Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. , 2014, Cell metabolism.

[82]  A. Longo,et al.  The Human Gene SLC25A29, of Solute Carrier Family 25, Encodes a Mitochondrial Transporter of Basic Amino Acids* , 2014, The Journal of Biological Chemistry.

[83]  Yong-jie Lu,et al.  Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. , 2014, Cancer Research.

[84]  Tijana Stankovic,et al.  Identification of Novel Genetic Alterations in Samples of Malignant Glioma Patients , 2013, PloS one.

[85]  P. Szlosarek,et al.  Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[86]  N. Avliyakulov,et al.  Proteomic Identification of Mitochondrial Targets of Arginase in Human Breast Cancer , 2013, PloS one.

[87]  Ralph J DeBerardinis,et al.  Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.

[88]  M. Lai,et al.  Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide , 2013, Molecular Cancer Therapeutics.

[89]  M. Wangpaichitr,et al.  Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction , 2013, Molecular Cancer Therapeutics.

[90]  Guoyao Wu,et al.  Nitric oxide and energy metabolism in mammals , 2013, BioFactors.

[91]  C. Ludwig,et al.  A Role for Cytosolic Fumarate Hydratase in Urea Cycle Metabolism and Renal Neoplasia , 2013, Cell reports.

[92]  P. Szlosarek,et al.  Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells , 2013, Cancer & metabolism.

[93]  S. Glynn,et al.  The yin and yang of nitric oxide in cancer progression. , 2013, Carcinogenesis.

[94]  A. Wilk,et al.  Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia , 2013, Leukemia.

[95]  Z. Mao,et al.  Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma , 2013, Journal of gastroenterology and hepatology.

[96]  Yigong Shi,et al.  A proposed role for glutamine in cancer cell growth through acid resistance , 2013, Cell Research.

[97]  Peilong Lu,et al.  L-glutamine provides acid resistance for Escherichia coli through enzymatic release of ammonia , 2013, Cell Research.

[98]  A. Erez Argininosuccinic aciduria: from a monogenic to a complex disorder , 2013, Genetics in Medicine.

[99]  T. Crook,et al.  Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma , 2013, Cell Death and Disease.

[100]  J. Wolchok,et al.  Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma , 2013, Investigational New Drugs.

[101]  A. Tsirigos,et al.  Mitochondria “fuel” breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells , 2012, Cell cycle.

[102]  D. Glass,et al.  Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.

[103]  Kyongmin Kim,et al.  NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells , 2012, Oncogene.

[104]  J. Gribben,et al.  Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis , 2012, Cell Death and Disease.

[105]  Hui Yang,et al.  Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. , 2012, Genes & development.

[106]  Hui-Kuan Lin,et al.  Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. , 2012, Cancer research.

[107]  Jeffrey W Pollard,et al.  KLF15 negatively regulates estrogen-induced epithelial cell proliferation by inhibition of DNA replication licensing , 2012, Proceedings of the National Academy of Sciences.

[108]  S. Fan,et al.  A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma , 2012, Investigational New Drugs.

[109]  G. Georgiou,et al.  Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. , 2012, Translational oncology.

[110]  G. Georgiou,et al.  Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells , 2012, Anti-cancer drugs.

[111]  Marshall Summar,et al.  Requirement of argininosuccinate lyase for systemic nitric oxide production , 2011, Nature Medicine.

[112]  P. Carmeliet,et al.  Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling , 2011, Cancer cell.

[113]  T. Wynn,et al.  Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase , 2011, The Journal of Immunology.

[114]  Abhishek K. Jha,et al.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011, Nature.

[115]  Abhishek K. Jha,et al.  Functional genomics reveals serine synthesis is essential in PHGDH-amplified breast cancer , 2011 .

[116]  Shengyue Wang,et al.  Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma , 2011, BMC Medical Genomics.

[117]  D. Wheatley,et al.  Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis , 2011, Pigment cell & melanoma research.

[118]  Brendan H. Lee,et al.  Argininosuccinate lyase deficiency—Argininosuccinic aciduria and beyond , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[119]  O. Stasyk,et al.  Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells , 2011, Anti-cancer drugs.

[120]  K. Robertson,et al.  DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. , 2011, American Journal of Pathology.

[121]  Damon H. May,et al.  Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics. , 2011, Journal of proteome research.

[122]  M. V. Vander Heiden Targeting cancer metabolism: a therapeutic window opens. , 2011, Nature reviews. Drug discovery.

[123]  A. Kavazis,et al.  Nitric oxide and AMPK cooperatively regulate PGC‐1α in skeletal muscle cells , 2010, The Journal of physiology.

[124]  I. Sheen,et al.  A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients , 2010, British Journal of Cancer.

[125]  B. Delage,et al.  Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer , 2010, International journal of cancer.

[126]  F. Izzo,et al.  Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  S. Curley,et al.  Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. , 2010, ACS chemical biology.

[128]  S. Hirohashi,et al.  Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma , 2010, Molecular Cancer Therapeutics.

[129]  R. Deberardinis,et al.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.

[130]  Xiaokui K. Zhang,et al.  Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. , 2009, American journal of clinical pathology.

[131]  Paolo Sassone-Corsi,et al.  Metabolism and cancer: the circadian clock connection , 2009, Nature Reviews Cancer.

[132]  N. Savaraj,et al.  Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4 , 2009, Molecular Cancer Therapeutics.

[133]  M. Beal Faculty Opinions recommendation of S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. , 2009 .

[134]  Takashi Nakagawa,et al.  SIRT5 Deacetylates Carbamoyl Phosphate Synthetase 1 and Regulates the Urea Cycle , 2009, Cell.

[135]  A. Godzik,et al.  S-Nitrosylation of Drp1 Mediates β-Amyloid-Related Mitochondrial Fission and Neuronal Injury , 2009, Science.

[136]  Akhilesh Pandey,et al.  A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. , 2008, Journal of proteome research.

[137]  A. Alavi,et al.  Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.

[138]  Y. Leung,et al.  Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. , 2007, Cancer research.

[139]  D. Fennell,et al.  In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion , 2006, Clinical Cancer Research.

[140]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[142]  O. Levillain,et al.  Localization and differential expression of arginase II in the kidney of male and female mice , 2005, Pflügers Archiv.

[143]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Margaret King,et al.  State of the art and perspectives , 2004, Machine Translation.

[145]  M. Stuschke,et al.  Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiation , 2003, International journal of cancer.

[146]  N. Rioseco-Camacho,et al.  Cloning and characterization of human ORNT2: a second mitochondrial ornithine transporter that can rescue a defective ORNT1 in patients with the hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, a urea cycle disorder. , 2003, Molecular genetics and metabolism.

[147]  A. Lavoinne,et al.  Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. , 2003, European journal of biochemistry.

[148]  J. Ochoa,et al.  Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine* , 2002, The Journal of Biological Chemistry.

[149]  J. Ochoa,et al.  Regulation of T cell receptor CD3zeta chain expression by L-arginine. , 2002, The Journal of biological chemistry.

[150]  C. Cabella,et al.  Agmatine modulates polyamine content in hepatocytes by inducing spermidine/spermine acetyltransferase. , 2001, European journal of biochemistry.

[151]  S. Almashanu,et al.  Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter , 1999, Nature Genetics.

[152]  S. Matsufuji,et al.  Agmatine Suppresses Proliferation by Frameshift Induction of Antizyme and Attenuation of Cellular Polyamine Levels* , 1998, The Journal of Biological Chemistry.

[153]  D. Reis,et al.  Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. , 1996, The Biochemical journal.

[154]  S. Klahr,et al.  Partial cloning and characterization of an arginine decarboxylase in the kidney. , 1995, Kidney international.

[155]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[156]  K. Chen,et al.  The evolutionary history of the first three enzymes in pyrimidine biosynthesis , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[157]  C. Allegra,et al.  Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. , 1987, The Journal of biological chemistry.

[158]  Holmes Fl,et al.  Hans Krebs and the discovery of the ornithine cycle. , 1980 .

[159]  F L Holmes,et al.  Hans Krebs and the discovery of the ornithine cycle. , 1980, Federation proceedings.

[160]  E. Glaser The randomized clinical trial. , 1972, The New England journal of medicine.

[161]  H. Krebs The History of the Tricarboxylic Acid Cycle , 2015, Perspectives in biology and medicine.

[162]  H. Krebs The citric acid cycle: A reply to the criticisms of F. L. Breusch and of J. Thomas. , 1940, The Biochemical journal.